Program

In-person AND virtual! – We are pioneering a new conference format that will connect in-person and virtual audiences to create a unique experience. Matching the innovation that comes through our members’ work, ISPOR is pushing the boundaries of innovation to design an event that works in today’s quickly changing environment. 

In-person registration included the full virtual experience, and virtual-only attendees will be able to tune into live in-person sessions and/or watch captured in-person sessions on-demand in addition to having a variety of virtual-only sessions to attend.

How Dual Branding of Drugs Impacts Reimbursement Decision in Multiple Myeloma?

Speaker(s)

Jagtap C1, Bhati P2, Wahal VP1
1Clarivate, Gurugram, HR, India, 2Clarivate, Gurgaon, HR, India

OBJECTIVES: To evaluate the impact of brand + brand drug combinations on reimbursement decisions in multiple myeloma.

METHODS: Health technology assessments (HTAs) of multiple myeloma drugs were conducted by G-BA (Germany), HAS (France), NICE (United Kingdom), SMC (Scotland), and TLV (Sweden) between June 2016 and September 2021, and were included in the analysis. HTAs with abbreviated submissions, terminated appraisals, non-submissions, and those without clinical evidence or reimbursement decisions were excluded. Descriptive statistics were reported.

RESULTS: A total of 30 HTAs of 6 brand + brand drug combinations (i.e., carfilzomib + lenalidomide, elotuzumab + lenalidomide, daratumumab + lenalidomide, ixazomib + lenalidomide, elotuzumab + pomalidomide, and isatuximab + pomalidomide) were included in the analysis. Of these brand + brand drug combinations, 87% (n = 26) were recommended and 13% (n = 4) were not recommended. All 6 brand + brand drug combinations that were submitted included dexamethasone as an adjunct drug. One hundred percent of the reviews submitted to G-BA (23% [n = 7]), HAS (40% [n = 12]), and TLV (3% [n =1]) were recommended.

Ninety percent (11/12) of HAS HTAs received an Actual Benefit Rating (SMR) of “Substantial.” NICE and SMC each comprised 17% (n = 5) of the total reviews; of those reviews, 60% (n = 3) were recommended and 40% (n = 2) were not recommended.

CONCLUSIONS: As per National Comprehensive Cancer Network (NCCN) guidelines, triple regimens (2 drug classes + steroids) should be used as the standard therapy for patients with multiple myeloma. Dual branding of drugs can provide value to payers and health care systems by improving patient access to novel treatments. Brand + brand targeted oncology drug combinations are most likely to receive positive decisions from HTA agencies.

Code

HTA27

Topic

Health Policy & Regulatory, Health Technology Assessment

Topic Subcategory

Decision & Deliberative Processes, Reimbursement & Access Policy

Disease

Oncology